Background: Statistical models based on item response theory were used to examine (a) the performance of individual Positive and Negative Syndrome Scale (PANSS) items and their options ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

with a statistically significant reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) total score after six weeks compared to placebo. It appears shareholders were spooked ...

PANSS is a scale for measuring schizophrenia symptom severity. Though treatment with three other doses of the drug (30 mg, 40 mg and 60 mg) also achieved a reduction in PANSS scores ranging from 1 ...

20 mg dose of ‘568 showed a statistically significant 7.5-point improvement in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo six weeks after dosing, with PANSS ...

The biotech based the target on the spectrum of PANSS scores seen in other studies, such as a phase 3 trial of BMS’ KarXT that reported an 8.4% improvement over placebo. Neurocrine saw a ...

Neurocrine’s Phase II study of ‘568 technically did not fail – the target 20mg/day dose did show a statistically significant decline in the Positive and Negative Syndrome Scale (or PANSS ...

It demonstrated a clinically meaningful and statistically significant reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 6 with a placebo-adjusted mean ...

The new data showed that the once-daily 20 mg dose of NBI-‘568 induced an average 18.2-point reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) after six weeks ...